Sun Pharmaceutical Industries Limited’s shares surged 4% to reach a record high of ₹1,420.85 on the NSE following robust performance by its subsidiary Taro Pharmaceutical Industries in Q3FY24.
Taro reported a Q3 profit of $20.2 million, a significant increase from $7.3 million in the same quarter of the previous year. The company’s Q3 revenue rose by 13% YoY, reaching $157.14 million.
Taro Pharma’s operating income for the third quarter was $15.83 million, compared to $1.3 million in the corresponding quarter of the previous fiscal, with margins at 10.8%.
Sun Pharma is set to acquire the remaining 21.52% stake in Taro Pharmaceutical Industries for ₹2,891.7 crore this month, consolidating its control over Taro. Sun Pharma currently holds 78.48% of Taro.
The deal, marking the end of nearly 17 years of negotiations, follows Sun Pharma’s previous attempts to gain full control over the US-listed generic drugmaker, which operates mainly in the United States and Canada.
Upon completion of the merger, expected in the first half of the year, Taro will become a privately held company and be delisted from the New York Stock Exchange.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.